Literature DB >> 2155293

Reactivation of latent infection and induction of recurrent herpetic eye disease in mice.

C Shimeld1, T J Hill, W A Blyth, D L Easty.   

Abstract

During primary ocular infection of mice with herpes simplex virus type 1 (HSV-1) strain McKrae, dendritic corneal ulcers developed and many eyes became permanently damaged. When primary infection had subsided, latent infection was detected in the three parts of the trigeminal ganglion and in the superior cervical ganglion. Such latently infected mice were treated with cyclophosphamide, dexamethasone and u.v. irradiation, or cyclophosphamide and dexamethasone alone. After treatment with immunosuppressive drugs and u.v. irradiation infectious virus was isolated from the ophthalmic part of the trigeminal ganglion, and in eyelids and eyewashings; recurrent herpetic eye disease was seen but only in eyes undamaged by primary infection. After treatment with cyclophosphamide and dexamethasone alone there was a lower incidence of virus isolated from eyewashings and no recurrent disease was seen. There was a good correlation between the pattern and distribution of recurrent lesions and the distribution of cells stained due to the presence of virus antigens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155293     DOI: 10.1099/0022-1317-71-2-397

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  49 in total

1.  Analysis of HSV Viral Reactivation in Explants of Sensory Neurons.

Authors:  Jesse H Arbuckle; Anne-Marie W Turner; Thomas M Kristie
Journal:  Curr Protoc Microbiol       Date:  2014-11-03

2.  Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explantation of trigeminal ganglia.

Authors:  T Valyi-Nagy; S Deshmane; A Dillner; N W Fraser
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

Authors:  Lbachir BenMohamed; Nelson Osorio; Ruchi Srivastava; Arif A Khan; Jennifer L Simpson; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

5.  IL-6 Contributes to Corneal Nerve Degeneration after Herpes Simplex Virus Type I Infection.

Authors:  Ana J Chucair-Elliott; Jeremy Jinkins; Meghan M Carr; Daniel J J Carr
Journal:  Am J Pathol       Date:  2016-08-03       Impact factor: 4.307

6.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.

Authors:  G C Perng; R L Thompson; N M Sawtell; W E Taylor; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle.

Authors:  Guey-Chuen Perng; Clinton Jones
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-15

9.  Herpes simplex virus type 1 mutant strain in1814 establishes a unique, slowly progressing infection in SCID mice.

Authors:  T Valyi-Nagy; S L Deshmane; B Raengsakulrach; M Nicosia; R M Gesser; M Wysocka; A Dillner; N W Fraser
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Induction of reactivation of herpes simplex virus in murine sensory ganglia in vivo by cadmium.

Authors:  R L Fawl; B Roizman
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.